Jazz Pharmaceuticals reported quarterly earnings of $5.71 per share which missed the analyst consensus estimate of $6.18 per share. The company reported quarterly sales of $1.208 billion which beat the analyst consensus estimate of $1.115 billion.
Jazz Pharmaceuticals raised its FY2026 sales guidance from $4.250 billion-$4.500 billion to $4.600 billion-$4.750 billion.
Jazz Pharmaceuticals shares gained 1.4% to $255.00 in pre-market trading.
These analysts made changes to their price targets on Jazz Pharmaceuticals following earnings announcement.
- Baird analyst Joel Beatty maintained the stock with an Outperform rating and raised the price target from $252 to $280.
- Barclays analyst Etzer Darout maintained the stock with an Overweight rating and raised the price target from $260 to $270.
- Needham analyst Ami Fadia maintained the stock with a Buy and raised the price target from $282 to $292.
Considering buying JAZZ stock? Here’s what analysts think:
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
